Must-read by

Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522

Elisa Agostinetto shared on X:

“Out in JCO a must-read by Marleen Kok on the limitations of KEYNOTE-522.

To control (financial) toxicity, agencies must limit trial designs where the relative contribution of each phase of treatment (pre vs. postop) cannot be established.”

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer published in JCO

Autors: Marleen Kok, Robbert-Jan Gielen,  Sylvia Adams, Jochen K. Lennerz, Priyanka Sharma, Sibylle Loibl, Erin Reardon, Gabe Sonke, Sabine Linn, Suzette Delaloge, Denis Lacombe, Tim Robinson, Sunil Badve, Miguel Martin, Justin M. Balko, Michail Ignatiadis, Giuseppe Curigliano, Antonio C. Wolff, Elizabeth A. Mittendorf, Sherene Loi, Lajos Pusztai, Sara M. Tolaney, and Roberto Salgado

Must-read by

Source: Elisa Agostinetto/X

Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.

Antonio C. Wolff Denis Lacombe Elisa Agostinetto Elizabeth A. Mittendorf Erin Reardon Gabe Sonke Giuseppe Curigliano JCO Jochen K. Lennerz Justin M. Balko KEYNOTE-522 Lajos Pusztai Marleen Kok Michail ignatiadis Miguel Martin Priyanka Sharma Robbert-Jan Gielen Roberto Salgado Sabine Linn Sara M. Tolaney Sherene Loi Sibylle Loibl Sunil Badve Suzette Delaloge Sylvia Adams Tim Robinson